Voluntary announcement - results of phase iii clinical study of efmedaglutide alfa injection in combination with metformin in chinese adult patients with type 2 diabetes mellitus presented in a short oral discussion at the 62nd annual meeting of the european association for the study of diabetes (easd 2026)
Filed with HKEX · Stock code 1093 ·
6ix hasn’t read this filing yet.
View original source (HKEXnews)Company analysis
Earlier from Cspc Pharmaceutical
- Voluntary announcement - phase ib clinical trial of jmt206 injection for weight management in adult patients with overweight or obesity officially initiated at the first study centre in china
- Voluntary announcement - recombinant herpes zoster vaccine (sys6052) obtains clinical trial approval in the U.S.
- Voluntary announcement - sys6077 injection obtains clinical trial approval in china
- Voluntary announcement - phase iii clinical trial of becotatug (jmt101) in combination with osimertinib for the first-line treatment of locally advanced or metastatic nsclc harbouring egfr exon 20 insertion mutations achieves positive topline results